http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20170003057-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_240ca7822c728d3f6565f8329e17b4da |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23V2200-312 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23L33-105 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K36-185 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K36-185 |
| filingDate | 2015-06-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_88eb74d50ad6424a771a288d30b42635 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4c0323beaa5f4491cbf05ccf1e193646 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3587aeaa18dd12ba3b136f64713e428f |
| publicationDate | 2017-01-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-20170003057-A |
| titleOfInvention | A composition comprising akebia quinata extract for preventing, improving or treating inflammation induced virulence of oral bacteria |
| abstract | The present invention relates to a composition for preventing, ameliorating or treating inflammation caused by oral bacterial toxicity, which comprises an extract of Aspergillus oryzae as an active ingredient. More specifically, it is an adhesin of Streptococcus mutans which is an oral bacterium and has an efficacy to prevent, ameliorate, or treat inflammation due to toxin, a virulence factor Ag I / II. ≪ RTI ID = 0.0 > vine extract. ≪ / RTI > The composition according to the present invention is a RAW 264.7 cell (1 x 10 6 cells / well) treated with 2.5 ug / mL of Ag I / II and contains 7.8 to 256 ug / mL of myrtle extract. To a composition for preventing, ameliorating or treating inflammation caused by inflammation. The composition according to the present invention is free from cytotoxicity, inhibits the production of NO and PGE 2 due to Ag I / II, inhibits the expression of iNOS, COX-2 and NF-κB which are proinflammatory mediators, and inflammatory cytokine TNF -α, IL-1β and IL-6, and promotes the expression of the anti-inflammatory cytokine IL-10. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20200002672-A |
| priorityDate | 2015-06-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 380.